Metamizol Mabo

Metamizole magnesium, the active ingredient in Metamizol Mabo, is a pyrazolone presented as an oral formulation for systemic use. It belongs to the analgesic and antipyretic therapeutic class and is employed to relieve moderate to severe pain and to reduce fever in adult patients.

GNH USA supplies Metamizol Mabo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and providing regulatory support for cross‑border procurement. The company’s distribution network covers Europe, Asia, Africa and the Americas, ensuring reliable supply chains.

Metamizole magnesium is used as an analgesic and antipyretic to manage pain and fever.

- Acute pain: provides rapid relief of moderate to severe pain when other analgesics are insufficient. - Fever: reduces high temperature in cases where standard antipyretics are ineffective. - Post‑operative pain: helps control pain after surgical procedures.

Metamizole magnesium may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild stomach upset. - Vomiting: occasional episodes. - Dizziness: transient light‑headedness. - Skin rash: mild erythema.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells. - Anaphylactic reaction: life‑threatening allergy. - Hepatic dysfunction: elevated liver enzymes. - Renal impairment: decreased kidney function.

When prescribing Metamizole Mabo, consider the following precautions.

- Assess patient history: check for previous hypersensitivity to pyrazolones. - Monitor blood counts: perform regular CBC to detect agranulocytosis early. - Avoid in severe liver disease: select alternative analgesics. - Use caution in renal impairment: adjust therapy as clinically indicated. - Pregnancy and breastfeeding: use only if potential benefits outweigh risks. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and direct sunlight.

Metamizole magnesium can interact with other medicines; awareness of the interaction level is important.

Major Interactions (Avoid): - Concurrent use with other myelosuppressive agents: increased risk of agranulocytosis. - Combination with ACE inhibitors: may enhance hypotensive effect. - Co‑administration with other NSAIDs: additive gastrointestinal toxicity.

Moderate Interactions (Monitor Closely): - Interaction with anticoagulants: may increase bleeding risk. - Use with diuretics: may affect electrolyte balance.